Status:
UNKNOWN
Eagle AF (Atrial Fibrillation) - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation
Lead Sponsor:
Prof. Dr. med. Bernd Lemke
Conditions:
Persistent Atrial Fibrillation
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The study aims to compare the results of pulmonary vein isolation (PVI) with a single technology approach in patients suffering from paroxysmal atrial fibrillation (PAF) with patients who have persist...
Eligibility Criteria
Inclusion
- failure of at least one specific class I or III antiarrhythmic drug (AAD)
- left atrial size \< 50 mm
- left ventricular ejection fraction \> 45%
- others
- specific for PAF: diagnosed with self-terminating episodes for no longer than 7 days
- specific for persistent AF: diagnosed with episodes of \> 7 days and \< 90 days
Exclusion
- AF secondary to a reversible cause of non-cardiac origin
- uncontrollable hypertension
- left atrial thrombus
- others
- specific for PAF: more than 1 electrical cardioversion in the year prior to enrollment
- specific for persistent AF more than 4 electrical cardioversions in the year prior to enrollment
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2017
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT02234102
Start Date
August 1 2014
End Date
June 1 2017
Last Update
August 21 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
St.Vinzenz-Hospital GmbH
Cologne, North Rhine-Westphalia, Germany, 50733
2
Märkische Kliniken GmbH, Klinik für Innere Medizin III
Lüdenscheid, North Rhine-Westphalia, Germany, 58515
3
Vivantes Netzwerk für Gesundheit GmbH
Berlin, State of Berlin, Germany, 13407